Mary E Keir

List of Publications by Year
in descending order

37 papers	10,230 citations	201674 27 h-index	330143 37 g-index
38 all docs	38 docs citations	38 times ranked	14984 citing authors

#	Article	IF	Citations
1	Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. Nature Medicine, 2022, 28, 766-779.	30.7	70
2	Dual targeting of lymphocyte homing and retention through Î±4Î²7 and Î±EÎ²7 inhibition in inflammatory bowel disease. Cell Reports Medicine, 2021, 2, 100381.	6.5	24
3	Regulation and Role of Î±E Integrin and Gut Homing Integrins in Migration and Retention of Intestinal Lymphocytes during Inflammatory Bowel Disease. Journal of Immunology, 2021, 207, 2245-2254.	0.8	29
4	The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational antiâ€integrin therapies. Medicinal Research Reviews, 2020, 40, 245-262.	10.5	60
5	The role of IL-22 in intestinal health and disease. Journal of Experimental Medicine, 2020, 217, e20192195.	8.5	217
6	The Importance of Molecular Immune Investigation in Therapeutic Clinical Development for Biomarker Assessment. Journal of Crohn's and Colitis, 2019, 13, 956-957.	1.3	0
7	Selective autophagy of the adaptor TRIF regulates innate inflammatory signaling. Nature Immunology, 2018, 19, 246-254.	14.5	99
8	Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, S653-S668.	1.3	56
9	AlphaE Integrin Expression Is Increased in the Ileum Relative to the Colon and Unaffected by Inflammation. Journal of Crohn's and Colitis, 2018, 12, 1191-1199.	1.3	14
10	Inflammatory Bowel Disease Susceptibility Gene C1ORF106 Regulates Intestinal Epithelial Permeability. ImmunoHorizons, 2018, 2, 164-171.	1.8	8
11	Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. Gut, 2017, 66, 2063-2068.	12.1	104
12	T Lymphocytes Expressing AlphaE Beta7 Integrin in Ulcerative Colitis: Associations With Cellular Lineage and Phenotype. Journal of Crohn's and Colitis, 2017, 11, 1504-1505.	1.3	11
13	Î±EÎ²7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis. Journal of Crohn's and Colitis, 2016, 11, jjw189.	1.3	43
14	Association Between Response to Etrolizumab and Expression of Integrin Î±E and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. Gastroenterology, 2016, 150, 477-487.e9.	1.3	133
15	Stratified medicine in inflammatory disorders: From theory to practice. Clinical Immunology, 2015, 161, 11-22.	3.2	21
16	Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet, The, 2014, 384, 309-318.	13.7	421
17	A randomised phase I study of etrolizumab (rhuMAb Î²7) in moderate to severe ulcerative colitis. Gut, 2013, 62, 1122-1130.	12.1	134
18	EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging. American Journal of Gastroenterology, 2013, 108, 1891-1900.	0.4	97

#	Article	IF	Citations
19	Functional Consequences of the Macrophage Stimulating Protein 689C Inflammatory Bowel Disease Risk Allele. PLoS ONE, 2013, 8, e83958.	2.5	17
20	CD28 Costimulation Regulates Genome-Wide Effects on Alternative Splicing. PLoS ONE, 2012, 7, e40032.	2.5	51
21	Anti-CD3 mAb treatment cures PDL1âˆ'/âˆ'.NOD mice of diabetes but precipitates fatal myocarditis. Clinical Immunology, 2011, 140, 47-53.	3.2	2
22	The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo. Journal of Immunology, 2011, 187, 1097-1105.	0.8	159
23	IFN-Î±-Induced Upregulation of CCR5 Leads to Expanded HIV Tropism In Vivo. PLoS Pathogens, 2010, 6, e1000766.	4.7	42
24	PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice. Journal of Clinical Investigation, 2010, 120, 2508-2515.	8.2	129
25	PD-1 and Its Ligands in Tolerance and Immunity. Annual Review of Immunology, 2008, 26, 677-704.	21.8	4,462
26	Bridging Toll-like- and B Cell-Receptor Signaling: Meet Me at the Autophagosome. Immunity, 2008, 28, 729-731.	14.3	10
27	Programmed Death 1 Ligand (PD-L) 1 and PD-L2 Limit Autoimmune Kidney Disease: Distinct Roles. Journal of Immunology, 2007, 179, 7466-7477.	0.8	73
28	Endothelial Programmed Death-1 Ligand 1 (PD-L1) Regulates CD8⁺T-Cellâ€"Mediated Injury in the Heart. Circulation, 2007, 116, 2062-2071.	1.6	221
29	PD-1 Regulates Self-Reactive CD8+ T Cell Responses to Antigen in Lymph Nodes and Tissues. Journal of Immunology, 2007, 179, 5064-5070.	0.8	212
30	Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses. Immunity, 2007, 27, 111-122.	14.3	1,464
31	PD-1 and its ligands in T-cell immunity. Current Opinion in Immunology, 2007, 19, 309-314.	5.5	388
32	Tissue expression of PD-L1 mediates peripheral T cell tolerance. Journal of Experimental Medicine, 2006, 203, 883-895.	8.5	1,042
33	The B7/CD28 costimulatory family in autoimmunity. Immunological Reviews, 2005, 204, 128-143.	6.0	129
34	Programmed Death-1 (PD-1):PD-Ligand 1 Interactions Inhibit TCR-Mediated Positive Selection of Thymocytes. Journal of Immunology, 2005, 175, 7372-7379.	0.8	122
35	Generation of CD3+CD8low Thymocytes in the HIV Type 1-Infected Thymus. Journal of Immunology, 2002, 169, 2788-2796.	0.8	40
36	IFN-Î± Secretion by Type 2 Predendritic Cells Up-Regulates MHC Class I in the HIV-1-Infected Thymus. Journal of Immunology, 2002, 168, 325-331.	0.8	87

#	Article	IF	Citations
37	A Membrane-bound Fas Decoy Receptor Expressed by Human Thymocytes. Journal of Biological Chemistry, 2000, 275, 7988-7993.	3.4	38